Investegate |Idorsia Pharmaceuticals Ltd Announcements | Idorsia Pharmaceuticals Ltd: Idorsia announces financial results for the first quarter 2021 – substantial progress made across the pipeline – launch preparations well underway
131.3 US GAAP revenue of CHF 7 million in the first quarter of 2021 consisted of contract revenue recognized in connection with the collaboration agreements with Neurocrine Biosciences, Inc. (CHF 1 million), Janssen Biotech, Inc. (CHF 3 million), Roche (CHF 2 million) and Mochida Pharmaceutical Co., Ltd (CHF 1 million) compared to a revenue of CHF 5 million in the first quarter of 2020. US GAAP operating expenses in the first quarter of 2021 amounted to CHF 129 million (CHF 116 million in the f...
Source: investegate.co.uk